GenMark Diagnostics, Inc. (GNMK) Shares Up 0% After Insider Buying Activity

For the current quarter Genmark Diagnostics (NASDAQ:GNMK) has high EPS estimates of $-0.22 in contradiction of low EPS estimates of $-0.32. GenMark Diagnostics, Inc. price was kept to a minimum $3.87 in intra-day trade and has returned -66.5% this year alone.

Among 12 analysts covering DaVita (NYSE:DVA), 1 have Buy rating, 3 Sell and 8 Hold. Zacks' sales averages are a mean average based on a survey of research firms that follow GenMark Diagnostics.

GenMark Diagnostics (NASDAQ:GNMK) last announced its quarterly earnings results on Thursday, November 2nd. The Cadian Capital Management Lp holds 3.99 million shares with $47.15M value, up from 3.19 million last quarter. The business had revenue of $12.36 million during the quarter, compared to the consensus estimate of $12.44 million.


While having a peek at profitability ratios Genmark Diagnostics (NASDAQ:GNMK) has trailing twelve month gross margin at 51.7%, its trailing twelve month operating margin stands at 0% whereas its trailing twelve month net profit margin spots at 0%. Over the trailing year, the stock is underperforming the S&P 500 by 21.11, and it's gotten there by action that has been less volatile on a day-to-day basis than most other stocks on the exchange. The difference between the expected and actual EPS was $-0.05/share, which represents an Earnings surprise of -15.6%.

A number of research analysts have recently issued reports on GNMK shares. BidaskClub lowered GenMark Diagnostics from a "hold" rating to a "sell" rating in a research note on Wednesday, July 12th. Cowen and Company raised GenMark Diagnostics from a "market perform" rating to an "outperform" rating and set a $17.00 price target for the company in a research note on Friday, September 16th. They set a "buy" rating and a $13.00 price target on the stock. BTIG Research restated a "buy" rating and set a $13.00 price target on shares of GenMark Diagnostics in a research note on Thursday, August 31st. New York-based Needham Inv Mngmt Ltd has invested 0.16% in GenMark Diagnostics, Inc (NASDAQ:GNMK). One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Currently, the stock has a 1 Year Price Target of $14.36. Genmark Diagnostics Inc now has $254.66M valuation. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of USA and worldwide copyright & trademark legislation. About 176,123 shares traded or 796.67% up from the average. As per Monday, June 26, the company rating was maintained by RBC Capital Markets. HighTower Advisors LLC now owns 2,074,347 shares of the company's stock worth $24,477,000 after buying an additional 2,028,046 shares during the last quarter. Following the sale, the chief financial officer now directly owns 138,096 shares of the company's stock, valued at approximately $1,305,007.20. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Jennifer Anne Williams sold 38,681 shares of the stock in a transaction on Friday, September 15th. The shares were purchased at an average cost of $11.80 per share, with a total value of $23,600.00. Vanguard Group Inc Incorporated owns 2.17 million shares for 0% of their portfolio. The disclosure for this purchase can be found here. The company traded as high as $4.26 and last traded at $4.10. JPMorgan Chase & Co. boosted its holdings in shares of GenMark Diagnostics by 15.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,097,767 shares of the medical equipment provider's stock worth $48,476,000 after purchasing an additional 559,629 shares during the last quarter. Jennison Associates LLC grew its holdings in shares of GenMark Diagnostics by 0.7% in the third quarter. The stock hit its twelve month high on 05/09/17, and twelve month low on 11/06/17. Insiders have sold 58,917 shares of company stock valued at $539,162 in the last quarter. Commercial Bank Of Ny Mellon Corporation has invested 0% of its portfolio in Perceptron, Inc. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions.

Related:

Comments

Latest news

Gen Jeep Wrangler interior revealed
Further down is the power window controls, and under that the drive modes for the four-wheel drive system. Most of this can also be handled by the UConnect system touchscreen at the top of the center stack.

Keith Urban Releases Uncompromising 'Female' Single
For a guy who grew up with no sisters in a house of boys, it's incredible how now I'm surrounded by girls. Now I am in a house that's all girls. "I am going to write songs", DiPiero said .

This Chinese Snapchat Competitor Just Bought $2B of Snap Stocks
Snap posted a $443.15 million net loss for the quarter, compared with $124.22 million in red ink in the year-ago period. UBS analyst Eric Sheridan downgraded Snap from neutral to sell, lowering the target share price from $12 to $7.

Square Inc (SQ) Q3 Profit And Revenue Top Expectations
Looking ahead, Square forecast Q4 EPS of $0.05 to $0.06, which is in-line with the $0.06 per share analysts are looking for. Net loss per share, basic and diluted, was $0.04, compared to a net loss per share of $0.09 in the third quarter of 2016.

Veterans Day Discounts, Deals And Freebies
Eat'n Park Restaurants are honoring all active and former US military personnel with a 10 percent discount through November 30. Texas Roadhouse - On Saturday November 11th, select from a free special veterans lunch menu including a beverage and sides.

Other news